Sintilimab vs Placebo Combined With Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic ESCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
BMJ 2022 Apr 19;377(xx)e068714, Z Lu, J Wang, Y Shu, L Liu, L Kong, L Yang, B Wang, G Sun, Y Ji, G Cao, H Liu, T Cui, N Li, W Qiu, G Li, X Hou, H Luo, L Xue, Y Zhang, W Yue, Z Liu, X Wang, S Gao, Y Pan, MP Galais, A Zaanan, Z Ma, H Li, Y Wang, L ShenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.